R&D Trends

Selecta Biosciences, 3SBio ink agreement for gout

Wednesday, June 18, 2014 12:49 PM

Selecta Biosciences, a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, has entered into an exclusive license with 3SBio, a biotechnology company researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

More... »

WIRB Copernicus Group

Pfizer, Cellectis enter global cancer immunotherapy collaboration

Wednesday, June 18, 2014 12:47 PM

Pfizer and Cellectis, a biopharmaceutical company focused on oncology, have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies directed at select targets.

More... »

CRF Health eCOA webinar series

TrovaGene, Dana-Farber Cancer Institute collaborate

Tuesday, June 17, 2014 11:12 AM

Trovagene has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.

More... »

TransCelerate BioPharma launches two new global initiatives

Monday, June 16, 2014 11:47 AM

TransCelerate BioPharma is launching two new global initiatives enabled by broad participation and collaboration across the R&D community: to develop a position on the best and most efficient methods for redacting privacy information found in clinical study reports and an approach for the anonymization of patient-level data shared with the broader healthcare community; and to develop a framework for a Quality Management System (QMS) specifically for clinical research to improve the quality and efficiency of clinical trials.

More... »

KalGene Pharmaceuticals forms multi-year collaboration for aggressive cancers

Friday, June 13, 2014 01:14 PM

KalGene Pharmaceuticals, a developer of a prognostic marker and companion therapeutic that specifically targets aggressive cancers, has formed a multi-stage and multi-year collaboration with the Center for Imaging Technology Commercialization (CIMTEC), Sunnybrook Research Institute (SRI) and the Ontario Cancer Biomarker Network (OCBN) at Queen's University.

More... »

Burke Medical Research Institute receives $2M NIH grant for spinal cord repair

Friday, June 13, 2014 01:11 PM

Scientists at the Burke Medical Research Institute in White Plains, N.Y., have received a $2 million grant from the NIH to study ways to enhance the survival of cell transplants for spinal cord repair. Cell transplants are a potential therapy for spinal cord injuries, which affect hundreds of thousands of Americans and for which few treatment options currently exist.

More... »

Janssen R&D, Viiv Healthcare collaborate on maintenance treatment for HIV

Friday, June 13, 2014 01:08 PM

Janssen R&D Ireland has entered into a collaboration with ViiV Healthcare to develop and commercialize a new, single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT) and ViiV's Integrase Inhibitor dolutegravir (marketed as TIVICAY) as the sole active ingredients for the maintenance treatment of people living with human immunodeficiency virus (HIV). The companies will further investigate development of this drug combination for pediatric use.

More... »

AstraZeneca in-licenses Synairgen's SNG001 for asthma in $232M deal

Thursday, June 12, 2014 01:38 PM

AstraZeneca has inked a global license agreement with Synairgen, a U.K. company specializing in respiratory diseases, for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. SNG001 supports the immune system by correcting a deficiency which makes patients vulnerable to respiratory tract viral infections.

More... »

X-Chem, Pfizer enter multi-target collaboration

Thursday, June 12, 2014 01:35 PM

X-Chem, a privately held biotechnology company applying its discovery capabilities to the generation of novel small molecule therapeutics, has announced a multi-target collaboration with Pfizer. The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases.

More... »

Seattle Children's Research Institute, Kineta partner for autoimmune research

Thursday, June 12, 2014 12:33 AM

Seattle Children's Research Institute and Kineta, a Seattle, Wash.-based privately held biotechnology company, have launched the Alliance for Children's Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases such as multiple sclerosis, type 1 diabetes and rheumatoid arthritis.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs